Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen

Infection and Immunity

Volumn 67, Issue 2, 1999, Pages 562-567

  Barnard, John P ^a,b   Friedlander, Arthur M ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG EFFICACY; GUINEA PIG; IMMUNOBLOTTING; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT PLASMID; SHUTTLE VECTOR; STRAIN DIFFERENCE; VACCINATION;

EID: 0032935609     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.2.562-567.1999     Document Type: Article

References (51)

1. Abalakin, V. A., N. P. Buravtseva, and B. L. Cherkasskii. 1990. The effect of the protective antigen of Bacillus anthracis on the formation of immunity under the action of live anthrax vaccines. Zh. Mikrobiol. Epidemiol. Immunobiol. 5:72-75.
2. Bartkus, J. M., and S. H. Leppla. 1989. Transcriptional regulation of the protective antigen gene of Bacillus anthracis. Infect. Immun. 57:2295-2300.
3. Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health 52:632-645.
4. Bradley, J. V. 1968. Distribution-free statistical tests, p. 195-203. Prentice-Hall Inc., Englewood Cliffs, N.J.
5. Bron, S., E. Luxen, and P. Swart. 1988. Instability of recombinant pUB110 plasmids in Bacillus subtilis: plasmid-encoded stability function and effects of DNA inserts. Plasmid 19:231-241.
6. Commission on the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, National Research Council. 1996. Guide for the care and use of laboratory animals. National Institutes of Health, Bethesda, Md.
7. Coulson, N. M., M. Fulop, and R. W. Titball. 1994. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL3261, affords protection against anthrax spore challenge. Vaccine 12:1395-1401.
8. Dunny, G. M., L. N. Lee, and D. J. LeBlanc. 1991. Improved electroporation and cloning vector system for gram-positive bacteria. Appl. Environ. Microbiol. 57:1194-1201.
9. Escuyer, V., and R. J. Collier. 1991. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59:3381-3386.
10. Finkelstein, A. 1990. Channels formed in phospholipid bilayer membranes by diphtheria, tetanus, botulinum and anthrax toxin. J. Physiol. (Paris) 84:188-190.
11. Friedlander, A. M. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126.
12. Gordon, V. M., S. H. Leppla, and E. L. Hewlett. 1988. Inhibitors of receptor mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun. 56:1066-1069.
13. Green, B. D., L. Battisti, T. M. Koehler, C. B. Thorne, and B. E. Ivins. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49: 291-297.
14. Hambleton, P., J. A. Carman, and J. Melling. 1984. Anthrax: the disease in relation to vaccines. Vaccine 2:125-132.
15. Horinouchi, S., and B. Weisblum. 1982. Nucleotide sequence and functional map of pC194, a plasmid that specifies inducible chloramphenicol resistance. J. Bacteriol. 150:815-825.
16. Hosmer, D. W., and S. Lemeshow. 1989. Applied logistic regression. John Wiky & Sons Inc., New York, N.Y.
17. Iacono-Connors, L. C., C. S. Schmaljohn, and J. M. Dalrymple. 1990. Expression of the Bacillus anthracis protective antigen gene by baculovirus and vaccinia virus recombinants. Infect. Immun. 58:366-372.
18. Iacono-Connors, L. C., S. L. Welkos, B. E. Ivins, and J. M. Dalrymple. 1991. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect. Immun. 59:1961-1965.
19. Ivins, B. E., J. W. Ezzell, Jr., J. Jemski, K. W. Hedlund, J. D. Ristroph, and S. H. Leppla. 1986. Immunization studies with attenuated strains of Bacillus anthracis. Infect. Immun. 52:454-458.
20. Ivins, B. E., and S. L. Welkos. 1986. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect. Immun. 54:537-542.
21. Ivins, B. E., and S. L. Welkos. 1988. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol. 4:12-19.
22. Ivins, B. E., S. L. Welkos, G. B. Knudson, and S. F. Little. 1990. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58:303-308.
23. Ivins, B. E., S. L. Welkos, S. F. Little, M. H. Crumrine, and G. O. Nelson. 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60:662-668.
24. Kado, C. I., and S.-T. Liu. 1981. Rapid procedure for detection and isolation of large and small plasmids. J. Bacteriol. 145:1365-1373.
25. Kaspar, R. L., and D. L. Robertson. 1987. Purification and physical analysis of Bacillus anthracis plasmids pX01 and pX02. Biochem. Biophys. Res. Commun. 149:362-368.
26. Klimpel, K. R., S. S. Molloy, G. Thomas, and S. H. Leppla. 1992. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA 89:10277-10281.
27. 2 and a trans-acting element activate transcription from one of two promoters. J. Bacteriol. 176:586-595.
28. Leppla, S. H. 1988. Production and purification of anthrax toxin. Methods Enzymol. 165:103-116.
29. Little, S. F., and G. B. Knudson. 1986. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun. 52:509-512.
30. Little, S. F., and J. R. Lowe. 1991. Location of the receptor-binding region of protective antigen from Bacillus anthracis. Biochem. Biophys. Res. Commun. 180:531-537.
31. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
32. McKenzie, T., T. Hoshino, T. Tanaka, and N. Sueoka. 1986. The nucleotide sequence of pUB110: some salient features in relation to replication and its regulation. Plasmid 15:93-103.
33. McKenzie, T., T. Hoshino, T. Tanaka, and N. Sueoka. 1987. A revision of the nucleotide sequence and functional map of pUB110. Plasmid 17:83-85.
34. Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Dreier. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39: 371-376.
35. Novak, J. M., and A. M. Friedlander. Unpublished data.
36. Pezard, C., P. Berche, and M. Mock. 1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59:3472-3477.
37. Pezard, C., M. Weber, J.-C. Sirard, P. Berche, and M. Mock. 1995. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 63:1369-1372.
38. Puziss, M., L. C. Manning, L. W. Lynch, E. Barclay, I. Abelow, and G. G. Wright. 1963. Large-scale production of protective antigen of Bacillus anthracis anaerobic cultures. Appl. Microbiol. 11:330-334.
39. Quinn, C. P., Y. Singh, K. R. Klimpel, and S. H. Leppla. 1991. Functional mapping of anthrax toxin lethal factor by in-frame insertional mutagenesis. J. Biol. Chem. 266:20124-20130.
40. Shlyakhov, E. N., and E. Rubinstein. 1994. Human live anthrax vaccine in the former USSR. Vaccine 12:727-730.
41. Singh, Y., S. H. Leppla, R. Bhatnagar, and A. M. Friedlander. 1989. Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and toxin-resistant cells. J. Biol. Chem. 264:11099-11102.
42. Singh, Y., K. R. Klimpel, C. P. Quinn, V. K. Chaudhary, and S. H. Leppla. 1991. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J. Biol. Chem. 266:15493-15497.
43. Stepanov, A. V., L. I. Marinin, A. P. Pomerantsev, and N. A. Staritsin. 1996. Development of novel vaccines against anthrax in man. J. Biotechnol. 44: 155-160.
44. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.
45. Turnbull, P. C. 1986. Anthrax vaccines: past, present and future. Vaccine 9: 533-539.
46. Turnbull, P. C., M. G. Broster, J. A. Carman, R. J. Manchee, and J. Melling. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52:356-363.
47. Uchida, I., K. Hashimoto, and N. Terakado. 1986. Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids. J. Gen. Microbiol. 132:557-559.
48. Uchida, I., J. M. Hornung, C. B. Thorne, K. R. Klimpel, and S. H. Leppla. 1993. Cloning and characterization of a gene whose product is a transactivator of anthrax toxin synthesis. J. Bacteriol. 175:5329-5338.
49. Uchida, I., T. Sekizaki, K. Hashimoto, and N. Terakado. 1985. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J. Gen. Microbiol. 131:363-367.
50. Welkos, S. L., and A. M. Friedlander. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5:127-139.
51. Welkos, S. L., N. J. Vietri, and P. H. Gibbs. 1993. Non-toxigenic derivatives of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain dependent virulence. Microb. Pathog. 14:381-388.